Critical

Allergen immunotherapy (subcutaneous) anaphylaxis / systemic reaction

Iatrogenic anaphylaxis · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Systemic allergic reaction to subcutaneous allergen immunotherapy (allergy shots), ranging from urticaria to life-threatening anaphylaxis with bronchospasm, respiratory failure and hypotension. Most reactions begin within 30 minutes of injection; rare but occasionally fatal. DRAFT for clinician review.

Figures & algorithms

Recognition & management
Recognition & management

Red flags

  • Hypotension
  • Bronchospasm / respiratory failure
  • Rapidly progressive symptoms
  • Known asthma, especially uncontrolled or FEV1 <70% predicted (strongest risk factor for fatal/near-fatal reactions)
  • Late-onset reaction (>30 minutes)
  • Patient on a beta-blocker or ACE inhibitor

Assessment

Differential diagnosis

  • Anaphylaxis from another cause
  • Vasovagal reaction
  • Large local injection-site reaction (not systemic)
  • Asthma exacerbation
  • Panic attack

Investigations

  • Clinical diagnosis — do not delay treatment; this is anaphylaxis management
  • Review which allergen/dose was given, asthma status (pre-injection FEV1/PEF), and beta-blocker / ACE-inhibitor use

Management

  • Immediate anaphylaxis treatment — IM epinephrine first-line, airway/oxygen, IV fluids, supine positioning
  • Observe for biphasic reaction
  • For beta-blocked patients not responding to epinephrine, consider glucagon
  • After recovery, arrange allergist review of dose/schedule and asthma control
  • Ensure higher-risk patients carry self-injectable epinephrine

Drugs & doses

IM epinephrine — first-line and time-critical (delayed or omitted epinephrine is associated with fatal outcomes). Treat per the Anaphylaxis entry (adjuncts: oxygen, IV fluids, antihistamines, inhaled bronchodilators, corticosteroids per protocol).
Glucagon — for refractory anaphylaxis in patients on beta-blockers (impaired epinephrine response).
Note: premedication (H1 antihistamine ± montelukast ± prednisone) reduces reactions mainly in accelerated/cluster build-up — a prevention measure, not acute treatment.

Disposition

Resuscitate and observe for a biphasic reaction (typically ≥4–6 hours, longer per severity). Discharge with an anaphylaxis action plan and epinephrine autoinjector for higher-risk patients; refer back to the prescribing allergist for dose adjustment, asthma optimisation and review before resuming immunotherapy.

Complications & pitfalls

  • Anaphylaxis
  • Biphasic reaction (10–23%)
  • Respiratory failure / death (rare — roughly 1 fatal per 6 million injections)
  • Complications of under-treatment

Exam pearls

  • 85–90% of serious reactions start within 30 minutes — hence the mandated 30-minute post-injection observation; the remainder within ~6 hours
  • Uncontrolled asthma is the dominant risk for fatal reactions — SCIT should be withheld when asthma is poorly controlled
  • Timely epinephrine is the key determinant of outcome (delayed in ~30% of fatal vs ~6% of near-fatal reactions)
  • Beta-blockers can make anaphylaxis refractory — consider glucagon
  • SCIT should only be given where staff/equipment can treat anaphylaxis; home administration is not recommended

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.